FMC Corporation 2025 Form 10-K Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2025. FMC Corporation is a global agricultural sciences company operating in a single segment, providing crop protection chemicals (insecticides, herbicides, fungicides) and plant health solutions. In February 2026, the Board authorized a strategic review to explore options, including a potential sale of the company, to unlock shareholder value. The company is also executing "Project Foundation," a multi-year restructuring program to optimize its manufacturing footprint and reduce structural costs.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $3,467.4 million | $4,246.1 million |
| Gross Margin | $1,283.0 million (37%) | $1,648.9 million (39%) |
| Net Loss (GAAP) | $(2,238.9) million | $341.1 million (Income) |
| Adjusted EBITDA (Non-GAAP) | $842.7 million | $902.6 million |
| Adjusted Earnings (Non-GAAP) | $372.0 million | $436.3 million |
| Total Debt | $4,074.9 million | $3,365.3 million |
| Cash and Equivalents | $584.5 million | $357.3 million |
| Free Cash Flow (Non-GAAP) | $(165.3) million | $613.5 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 18% year-over-year. Excluding one-time commercial actions related to the India business held for sale, revenue decreased 8%, driven by a 6% price decline (partially due to "cost-plus" contract adjustments and generic competition) and flat volumes.
- Significant Impairments: The company recorded a $1,356.2 million write-off of its entire goodwill balance due to a significant decrease in stock price. Additionally, $522 million in charges were recorded related to the India commercial business held for sale, including $194.8 million in asset impairment and $319.8 million in commercial adjustments.
- Restructuring Charges: Total restructuring and other charges were $1,960.3 million in 2025, compared to $219.8 million in 2024. This includes $172.0 million for "Project Foundation" and $99.1 million for "Project Focus."
- Dividend Reduction: In October 2025, the Board reduced the quarterly dividend to $0.08 per share to prioritize debt reduction.
Guidance, Outlook, and Risks
- Strategic Review: The company is exploring strategic options, including a sale, to enhance shareholder value. This process is preliminary with no assurance of a transaction.
- India Divestiture: The commercial business in India is classified as "held for sale" with a target closing in 2026. The company plans to maintain active ingredient manufacturing in India and supply the buyer.
- 2026 Priorities: Focus on strengthening the balance sheet via debt paydown, managing the post-patent transition for Rynaxypyr active, and advancing new active ingredients (Isoflex, fluindapyr, Dodhylex, rimisoxafen).
- Risks: Key risks include generic competition eroding margins on core portfolio products, regulatory changes, supply chain disruptions, and the potential failure to complete the India divestiture or strategic review on favorable terms. Credit ratings have been downgraded below investment grade, increasing borrowing costs.
Investor Verification Checklist
- Goodwill Impairment: Verify the assumptions used in the discounted cash flow model that triggered the $1.36 billion goodwill write-off.
- India Divestiture Terms: Monitor the progress of the India commercial business sale and the terms of the supply agreement with the eventual buyer.
- Debt Covenants: Review the amended Revolving Credit Facility covenants (leverage ratio up to 6.00, interest coverage down to 2.00) and compliance status.
- Generic Competition: Assess the impact of expired patents on Rynaxypyr and Cyazypyr active ingredients on future pricing and volume.
- Restructuring Costs: Track the execution of "Project Foundation" against the estimated total pre-tax charges of $560 million to $635 million.